Lilly completes acquisition of Akouos, expanding efforts to help people with genetic conditions
INDIANAPOLIS, Dec. 1, 2022 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly’s efforts in the area of genetic drugs to include Akouos’ portfolio of potential first-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including …
